Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIBRANT: Aflibercept for Macular Edema Secondary to BRVO
NCT01521559Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2012
- Primary completion
- Aug 2013
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 3 trial of aflibercept in macular edema, sponsored by Regeneron Pharmaceuticals. Started Apr 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01521559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521559.